Innovations in malaria vaccine development (IMV)
Ended Definitive Contract Awarded Last action
- Contract number
- 7200AA20C00017
- Awardee
-
Path UEI PD3VNAABZJL7
- Awarding agency
-
Office of the Assistant Administrator
Bureau for Management, US Agency for International Development
- Obligated
- $19,973,963
Award facts
- Opportunity
-
- Innovations in Malaria Vaccine Development (IMV) Special Notice · GHBAA2018ADDENDUM03 · Posted May 17, 2019
- Contract value 73% obligated
- $27,321,246.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Bureau for Global Health Washington Office, US Agency for International Development
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Two Step
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Seattle, WA 98121, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Funding Only Action | $4,923,978 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $3,831,047 | |
| Funding Only Action | $4,392,588 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $3,988,102 | |
| Other Administrative Action | $0 | |
| Original award | $2,838,248 |
Show all 11
About this award
This is a $27,321,246 cost-plus-fixed-fee contract awarded by the U.S. Agency for International Development (USAID) to Path, a global nonprofit organization, for the "Innovations in Malaria Vaccine Development (IMV)" program. The contract aims to support novel and innovative approaches to malaria vaccine development, encompassing preclinical development through proof-of-principle clinical studies to motivate advanced development of a deployable, effective malaria vaccine. Key subcontractors include the University of Oxford, Statens Serum Institut, Scripps Research Institute, and the University of Texas at Austin. The overall goal is to demonstrate proof of concept for a malaria vaccine that reduces morbidity and mortality caused by Plasmodium falciparum with at least 75% efficacy and evidence of affordability. This contract was competitively awarded and does not utilize any set-aside designations.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| University Of Oxford | $1,985,512 | |
| Statens Serum Institut | $272,685 | |
| University Of Oxford | $188,008 | |
| Statens Serum Institut | $135,340 | |
| Scripps Research Institute | $678,751 | |
| University Of Oxford | $3,745,764 | |
| Statens Serum Institut | $164,425 | |
| Scripps Research Institute | $189,378 | |
| University Of Oxford | $1,031,914 | |
| University Of Oxford | $2,300,128 | |
| Statens Serum Institut | $142,779 | |
| Scripps Research Institute | $324,144 | |
| University Of Texas At Austin | $502,790 | |
| The Johns Hopkins University | $397,987 | |
| University Of Oxford | $295,468 | |
| University Of Oxford | $1,117,326 |
Show all 16
Quick answers
Who was awarded contract 7200AA20C00017?
7200AA20C00017 was awarded to Path by Office of the Assistant Administrator (Bureau for Management) on June 18, 2020.
How much is contract 7200AA20C00017 worth?
The government has obligated $19,973,963 on 7200AA20C00017. Its current value, with exercised options, is $27,321,246.
Which agency awarded contract 7200AA20C00017?
Office of the Assistant Administrator (Bureau for Management) awarded 7200AA20C00017, with funding from Bureau for Global Health (Washington Office).
Was contract 7200AA20C00017 competed?
The extent of competition for 7200AA20C00017 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award